Define Predictors for Posttransplant Diabetes Mellitus Study

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Antwerp

About this trial

The primary aim of this prospective, multicentre study is to develop an accurate and convenient tool to predict the risk of PTDM at 3 months post-transplant, based on information on the day of transplantation (day 0).

In order to create such model, we will start by identifying individual predictor variables at the day of transplantation and subsequently explore the optimal combination of these predictors in multivariable models.

Secondary objectives include:

* Compare the performance of the model based on predictor variables at day 0 with existing models for prediction of PTDM (Chakkera, San Antonio Diabetes Prediction Model and Framingham Offspring Study Diabetes Mellitus algorithm) * Explore the glucose level evolution during the first 2 weeks after transplantation using continuous glucose monitoring, and its relationship with baseline patient characteristics and immunosuppressant drug use. * Evaluate the added value of incorporating information on glucose levels in the first and second weeks post-transplant to improve the PTDM prediction model. * Identify predictors for early post-transplant hyperglycemia (first 2 weeks post-transplantation) * Explore the correlation between early post-transplant hyperglycemia (fasting glycemia, pre-dinner glycemia) and PTDM at 3 months

Eligibility criteria

Qualifiers

Adult patients (≥18 years) with end stage kidney disease undergoing kidney transplantation with a deceased or living donor

Signed informed consent

Initial therapy with at least tacrolimus and corticosteroids

Disqualifiers

Patients with a diagnosis of diabetes mellitus (either type 1 or type 2) prior to kidney transplantation

Treatment with GLP1-RA for weight losing purposes

Patients receiving a multi-organ transplantation

ABO incompatibility

Trial design

Treatments tested in this trial

  • continuous glucose monitoring

Treatment groups

No treatment groups listed

Sponsors and collaborators

University Hospital, Antwerp

Lead sponsor

Universitair Ziekenhuis Brussel

Collaborator

University Ghent

Collaborator

Universitaire Ziekenhuizen KU Leuven

Collaborator

HUB

Collaborator

Université Catholique de Louvain

Collaborator

Centre Hospitalier Universitaire de Liege

Collaborator